Home  |  Contact

UniProtKB/Swiss-Prot P02766: Variant p.Val50Leu

Transthyretin
Gene: TTR
Variant information

Variant position:  50
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Valine (V) to Leucine (L) at position 50 (V50L, p.Val50Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In AMYL-TTR; amyloid polyneuropathy.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  50
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  147
The length of the canonical sequence.

Location on the sequence:   CPLMVKVLDAVRGSPAINVA  V HVFRKAADDTWEPFASGKTS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTS

Chimpanzee                    CPLMVKVLDAVRGSPAINVAVHVFKKAADETWEPFASGKTS

Mouse                         CPLMVKVLDAVRGSPAVDVAVKVFKKTSEGSWEPFASGKTA

Rat                           CPLMVKVLDAVRGSPAVDVAVKVFKKTADGSWEPFASGKTA

Pig                           CPLMVKVLDAVRGSPAVNVGVKVFKKAADGTWEPFALGKTS

Bovine                        CPLMVKVLDAVRGSPAANVGVKVFKKAADETWEPFASGKTS

Rabbit                        CPLMVKVLDAVRGSPAVDVSVHVFKKAADETWEPFASGKTS

Sheep                         CPLMVKVLDAVRGSPAANVGVKVFKKAADETWEPFASGKTS

Chicken                       CPLMVKVLDAVRGSPAANVAVKVFKKAADGTWQDFATGKTT

Xenopus laevis                CPLMVKVLDAVRGIPAANLLVNVFRQTESGKWEQITSGKTT

Xenopus tropicalis            CPLMVKVLDAVRGIPAANLLVQVFRNT-EGNWELISSGKTT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 21 – 147 Transthyretin
Binding site 35 – 35 Thyroid hormones
Modified residue 62 – 62 4-carboxyglutamate; in a patient with Moyamoya disease
Beta strand 49 – 55


Literature citations

A novel transthyretin mutation at position 30 (Leu for Val) associated with familial amyloidotic polyneuropathy.
Murakami T.; Atsumi T.; Maeda S.; Tanase S.; Ishikawa K.; Mita S.; Kumamoto T.; Araki S.; Ando M.;
Biochem. Biophys. Res. Commun. 187:397-403(1992)
Cited for: VARIANT AMYL-TTR LEU-50;

Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy.
Tachibana N.; Tokuda T.; Yoshida K.; Taketomi T.; Nakazato M.; Li Y.F.; Masuda Y.; Ikeda S.;
Amyloid 6:282-288(1999)
Cited for: VARIANTS AMYL-TTR LEU-50; VAL-53; ALA-58; ARG-70; GLY-117 AND SER-117; IDENTIFICATION BY MASS SPECTROMETRY;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.